21st Annual Cancer Progress Conference
March 16-17, 2010
Program
Program Moderators:
Jeremy P. Goldberg, JPG Healthcare LLC
Mark Simon, President, Williver Group LLC
Keynote Presentation: Cancer
Stem Cells and the Development of High-Grade Malignancy
Robert A. Weinberg, PhD, Member, Whitehead Institute, Professor of
Biology, MIT
Keynote Presentation: Taking the
Cellulite Out of Cancer
Daniel D. Von Hoff, MD, Physician-in-Chief, Director, Translational Research,
TGen, Clinical Professor of Medicine, University of Arizona
Panel Discussion: Steps on the Promise of Targeted Therapies
Co-Moderators: Markus Goebel, MD, PhD, Managing Director, Novartis Venture
Fund
Prof. Michel Aguet, MD, Director, Swiss Institute for Experimental Cancer
Research (ISREC)
Neal Rosen, MD, PhD, Enid A. Haupt Chair in Medical Oncology,
TORC1/2 - Christian Rommel, PhD, CSO, Intellikine
PI3K Delta Inhibitor - Albert S. Yu, MD, VP, Medical Affairs & CMO, Calistoga Pharmaceuticals
AKT Inhibitor - Li Yan, MD, PhD, Director, Clinical Oncology, Merck
PMT - New enzyme class - Robert Copeland, PhD, EVP & CSO, Epizyme
BRAF Inhibitor for Melanoma - K. Peter Hirth, PhD, CEO, Plexxikon
ALK Inhibitors - Martine George, MD, MSc, VP,
Medical Affairs, Pfizer Oncology
Panel Discussion: Patient Stratification: Impact on Drug Development and
Commercialization
Moderator: Richard Gaynor, MD, VP, Cancer Research & Clinical
Investigation, Eli Lilly
Joseph R.
Nevins, PhD, Barbara Levine Professor for Breast Cancer, Director, IGSP
Center for Applied Genomics and Technology, Duke University Medical Center
David Schenkein, MD, PhD, CEO, Agios Pharmaceuticals
Steven J. Heller, Global Marketing Leader, Oncology GSM, Worldwide Strategic
Marketing, Johnson & Johnson
Matthew Meyerson, MD, PhD, Professor of Pathology, Harvard Medical School/Broad
Institute
Novel Antiandrogens for Prostate Cancer
Charles Sawyers, MD, Chairman,
Special Presentation: New
Institutional and Technical Approaches to Tackle the Cancer Problem
Robert G. Urban, PhD, Executive Director, David H. Koch Institute for
Integrative Cancer Research, MIT
Pearl Huang, PhD, Vice President, Franchise Integrator, Oncology, Merck
The
Challenge
of Targeting
EGFR: Lessons
Learnt
and Future
Directions
With
Gefitinib
Alison A. Armour, MD, Iressa Medical Science
Director, AstraZeneca
,UK
Panel Discussion: Genomic Strategies for Rational Combinations of Targeted
Therapies
Moderator: David C. Heimbrook, PhD, VP Oncology Global
Therapeutic Area, Roche
David Solit,
Jeffrey Engelman MD, PhD, Assistant Professor in Medicine at Harvard Medical
School, Director, Thoracic Oncology, Massachusetts General Hospital Cancer
Center
Brian Leyland-Jones, MD, PhD, Winship Cancer Institute,
Colin Hill, CEO, Gene Network Sciences
Stuart Lutzker, MD, PhD, VP BioOncology Exploratory Clinical Development,
Genentech
Panel Discussion:
Panel
Moderator: Steven D. Averbuch, MD, VP Oncology Transition Strategy &
Development and Head, Pharmacodiagnostics Global Clinical Research,
Bristol-Myers Squibb
Brian Leyland-Jones, MD, PhD, Winship Cancer Institute, Emory
Daniel J. Sargent, PhD, Professor of Oncology, Professor of Biostatistics, Mayo
Clinic
Neil Gunn, MSc, PhD, Vice President Global Business, Roche Molecular Systems
Mark Ratain, MD, Leon O. Jacobson Professor of Medicine, Chairman, Committee on
Clinical Pharmacology and Pharmacogenomics, University of Chicago
Randy Scott, Executive Chairman, Genomic Health
Elizabeth Mansfield, PhD, Senior Genomics Advisor, Office of FDA Chief
Scientist, FDA
Felix W. Frueh, PhD, Vice President, R&D - Personalized Medicine, Medco
Health Solutions, Inc.
Bruce Quinn, MD, Senior Health Policy Specialist, Foley Hoag, LLP
Panel Discussion: Adaptive Trial Design
Moderator: Eric Rubin, MD, VP Oncology Clinical Research, Merck
Mark Ratain, MD, Leon O. Jacobson Professor of Medicine, Chairman, Committee on
Clinical Pharmacology and Pharmacogenomics, University of Chicago
Donald Berry, PhD, Head, Division of Quantitative Sciences and Chairman,
Department of Biostatistics and Frank T. McGraw Memorial Chair of Cancer
Research, MD Anderson Cancer Center
Roy S. Herbst, MD, PhD, Professor of Medicine, Department of Thoracic Head and Neck
Cancer, Division of Cancer Medicine, MD Anderson Cancer
Center
Sue-Jane Wang, PhD, Associate Director for Adaptive Design and Pharmacogenomics,
Office of Biostatistics, OTS/CDER/FDA (invited)
New Imaging Strategies Beyond RECIST
David Geho, MD, PhD, Clinical Project Leader, General Electric Corporation
Lawrence H. Schwartz, MD,
James
Picker Professor & Chairman, Department of Radiology,
Nola Hylton, PhD, Professor of Radiology, Director, MRI Research Program,
UCSF
Wendy Hayes, DO, Imaging Director, Discovery Medicine and Clinical
Pharmacology, Bristol-Myers Squibb
Gary Kelloff, MD, Special Advisor, Division of Cancer Treatment & Diagnosis,
NCI, NIH
Market
Access
Under
Healthcare
Reform
Lee Blansett, Senior Vice President, Kantar Health
Registration Form
Preliminary Agenda
Discussion
Sponsors Communitech